Safety of Atorvastatin in Patients With Stable Systemic Autoimmune Myopathies A Pilot Longitudinal Study

Autor(es)

Pires Borges, Isabela Bruna ^[1] ; de Oliveira, Diego Sales ^[1] ; Misse, Rafael Giovani ^[1] ; dos Santos, Alexandre Moura ^[1] ; Costa Hong, Valeria Aparecida ^[2] ; Bortolotto, Luiz Aparecido ^[2] ; Shinjo, Samuel Katsuyuki ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Fac Med FMUSP, Div Rheumatol, SP Av Dr Arnaldo 455, 3 Andar, Sala 3150, BR-01246903 Sao Paulo - Brazil

^[2] Univ Sao Paulo, Fac Med, Hosp Clin HCFMUSP, Hypertens Unit, Inst Coracao, Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: JCR-JOURNAL OF CLINICAL RHEUMATOLOGY; v. 27, n. 6, p. S236-S241, SEP 2021.
• Citações Web of Science: 0

Resumo

Background/Objective: Patients with systemic autoimmune myopathies (SAMs) have high prevalence of dyslipidemia and, consequently, possible endothelial dysfunction and vascular stiffness. Our objective was to evaluate the possible benefits on endothelial function and vascular stiffness, as well as adverse effects of atorvastatin in SAMs. Methods: Apilot longitudinal, double-blind, randomized, placebo-controlled study was conducted. Twenty-four of 242 patients were randomized at a 2:1 ratio to receive atorvastatin (20 mg/d) or placebo for a period of 12 weeks. Demographic data, comorbidities, and clinical and laboratory parameters, as well as endothelial function and arterial stiffness, were evaluated. Results: Of the 24 randomized patients, 4 patients were excluded, with remaining 20 patients (14 in the atorvastatin group and 6 in the placebo group). The mean age of the patients was 49.0 years, and 75% of the patients were female. At baseline, the demographic data, disease status, treatment, cardiovascular comorbidities, and risk factors were comparable between the atorvastatin and placebo groups. After 12 weeks of follow-up of atorvastatin therapy, no improvements were observed for endothelial function and arterial stiffness in either group (p > 0.05). As expected, a significant reduction in total and low-density lipoprotein cholesterol levels was observed. During the study, no clinical intercurrences or disease relapses were observed in either group. Conclusions: The atorvastatin drug attenuated low-density lipoprotein cholesterol without worsening clinical outcomes in SAMs. No change was observed for endothelial function and arterial stiffness. Additional studies, with long-term follow-up time and different atorvastatin dosage, are needed to corroborate the results of this study. (AU)

• Processo FAPESP: 16/19771-5 - Efeitos do treinamento físico no conteúdo lipídico e na resistência à ação da insulina do músculo esquelético de pacientes com miopatias inflamatórias idiopáticas: ensaio clínico controlado e randomizado
• Beneficiário: Diego Sales de Oliveira
• Linha de fomento: Bolsas no Brasil - Doutorado
• Processo FAPESP: 16/23574-0 - Efeitos do treinamento físico na função endotelial e nas propriedades funcionais de grandes artérias de pacientes com miopatias inflamatórias idiopáticas: Ensaio clínico controlado e randomizado
• Beneficiário: Rafael Giovani Misse
• Linha de fomento: Bolsas no Brasil - Mestrado
• Processo FAPESP: 18/08735-3 - Capacidade aeróbia e exercício de força na arterite de Takayasu: relações e impactos nos desfechos clínicos, laboratoriais e extensão das lesões vasculares
• Beneficiário: Alexandre Moura dos Santos
• Linha de fomento: Bolsas no Brasil - Mestrado
• Processo FAPESP: 17/13109-1 - Impacto do treinamento físico na resistência a ação da insulina, conteúdo lipídico, angiogênese e fibrogênese do músculo esquelético de pacientes com miopatias inflamatórias idiopáticas
• Beneficiário: Samuel Katsuyuki Shinjo
• Linha de fomento: Auxílio à Pesquisa - Regular
• Processo FAPESP: 16/20371-1 - Efeito do uso de hipolipemiantes na função endotelial e na rigidez vascular de pacientes com dermatomiosite e polimiosite: estudo prospectivo, duplo cego, randomizado e controlado
• Beneficiário: Isabela Bruna Pires Borges
• Linha de fomento: Bolsas no Brasil - Mestrado